Abstract: With the growing exchange of digital images in the Internet of Things (IoT), securing sensitive data, particularly medical images, has become critical. These images are essential for ...
The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the ...
Abstract: Graph representation learning is a fundamental research theme and can be generalized to benefit multiple downstream tasks from the node and link levels to the higher graph level. In practice ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results